UK markets closed

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
11.06-0.62 (-5.31%)
At close: 04:00PM EST
11.46 +0.40 (+3.62%)
After hours: 07:55PM EST
Full screen
Trade prices are not sourced from all markets
Previous close11.68
Open11.47
Bid11.00 x 900
Ask11.49 x 1000
Day's range11.01 - 11.83
52-week range5.63 - 20.49
Volume537,147
Avg. volume990,754
Market cap2.105B
Beta (5Y monthly)2.50
PE ratio (TTM)N/A
EPS (TTM)-1.75
Earnings date26 Apr 2023 - 01 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est17.62
  • EQS Group

    CureVac Welcomes Myriam Mendila as New Chief Development Officer

    Issuer: CureVac / Key word(s): Personnel01.02.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Welcomes Myriam Mendila as New Chief Development Officer Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experienceTÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribo

  • EQS Group

    CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®

    Issuer: CureVac / Key word(s): Patent31.01.2023 / 14:12 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis® CureVac recognized as a Top 100 innovator in acknowledgment of the company’s innovative strength and extensive intellectual property portfolio The company holds one of broadest intellectual property portfolios in mRNA technologyTÜBINGEN, Germany/ BOSTON, USA – January 31, 2023 – CureVac N.V

  • EQS Group

    CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs (news with additional features)

    Issuer: CureVac / Key word(s): Study30.01.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants i